| 1.02 |
-0.01
|
-0.97% | 1,097,632 | Market data is delayed by at least 20 minutes. | ||
| Last | Change | / | % Change | Volume |
|
Exclusive Features |
||
| When you open a Scottrade account, you will be able to trade, add stocks to a watch list, set alerts and get real-time quotes. |
Or
|
|
|
--/--
Bid/Size |
--/--
Ask/Size |
1.01
Price Open |
||
|
1.03
Previous Close |
1.03
Day High |
0.98
Day Low |
||
|
0.90
Beta (5yr) |
4.54/6/5/09
52wk High/Date |
0.26/2/18/09
52wk Low/Date |
||
|
135.4 Million
Market Capitalization |
132.7 Million
Shares Outstanding |
182.37
Volatility Avg (1 Year) |
||
|
2.2 Million
Avg Vol (10 day) |
NM
P/E Ratio |
-0.1594
EPS (TTM) |
||
|
Hemispherx Biopharma, Inc does not pay dividends. |
||||
Get the following exclusive content at no additional cost with your Scottrade account:
- Standard & Poor's STARS Rating for the featured stock
- Research reports from Reuters and Standard & Poor's
- Market Edge Second Opinion Weekly Report
Hemispherx Biopharma, Inc vs. Peers
| Company | Market Cap | YTD Price Performance |
|
HEB
Hemispherx Biopharma, Inc |
128.8M | |
|
PFE
Pfizer Inc. |
148.2B | |
|
MRK
Merck & Co., Inc. |
111.4B | |
|
GILD
Gilead Sciences, Inc. |
41.7B | |
|
AVII
AVI BioPharma, Inc. |
125.2M |
Company Background
Hemispherx Biopharma, Inc. (Hemispherx) is a biopharmaceutical company engaged in the clinical development, manufacture, marketing and distribution of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's products include Ampligen and Alferon N and Injection. Ampligen includes application as a treatment for Chronic Fatigue Syndrome (CFS) and as a vaccine enhancer(adjuvant) for both therapeutic and preventative vaccine development. Alferon N is an indicator for refractory or recurring genital warts. Alferon LDO (Low Dose Oral) is an application under early stage development targeting influenza and viral diseases. Ampligen is an experimental drug undergoing clinical development for the treatment of CFS.
Brokerage Products and Services offered by Scottrade, Inc. - Member FINRA and SIPC
Online market and limit stock trades are just $7 for stocks priced $1 and above.
Any specific securities, or types of securities, used as examples are for demonstration purposes only. No information on this Web site should be considered a recommendation or None of the information provided should be considered a recommendation or solicitation to invest in, or liquidate, a particular security or type of security.
Investors should consider the investment objectives, risks, and charges and expenses of a mutual fund carefully before investing. A mutual fund's prospectus contains this and other information about the mutual fund. Prospectuses are available through our trading site or through a Scottrade branch office. The prospectus should be read carefully before investing. No transaction fee (NTF) funds are subject to the terms and conditions of the NTF funds program. Scottrade is compensated by the funds participating in the NTF program through recordkeeping, shareholder, or SEC 12b-1 fees.
Investors should consider the investment objectives, charges, expense, and unique risk profile of an Exchange Traded Fund (ETF) carefully before investing. Leveraged and Inverse ETFs may not be suitable for long-term investors and may increase exposure to volatility through the use of leverage, short sales of securities, derivatives and other complex investment strategies. A prospectus contains this and other information about the ETF and should be obtained from the issuer. The prospectus should be read carefully before investing.
Margin trading involves interest charges and risks, including the potential to lose more than deposited, or the need to deposit additional collateral in a falling market. Margin Disclosure Statement (PDF) is available for download, or it is available at one of our branch offices. It contains information on our lending policies, interest charges, and the risks associated with margin accounts.
Options involve risk and are not appropriate for all investors. Detailed information about the risks associated with options can be found in the Scottrade Options Application and Agreement, Brokerage Account Agreement, or by downloading the Characteristics and Risks of Standardized Options and Supplements (PDF) from The Options Clearing Corporation, or by requesting a copy from your local branch office. Supporting documentation for any claims will be supplied upon request.
Market volatility, volume, and system availability may impact account access and trade execution.
Testimonials may not be representative of the experience of other clients and are no guarantee of future performance or success.




